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Obesity is known to be strongly correlated with immunodeficiency. which is
particularly problematic for obese cancer patients with cancers typically
responsive to immunotherapy. Ways to circumvent obesity-linked
immunodeficiency are vital in cancer treatment for such individuals.
A promising approach to combating obesity-induced immunodeficiency is through
reducing obesity itself through medication. Another approach is through
reintroducing cytokines involved in activation, differentiation, or growth of immune
cells.
Tumor necrosis factor (TNF) related weak inducer of apoptosis, also known as
TWEAK or TNFSF12, is such a cytokine. It not only has downstream signaling
pathways that promote immune cell proliferation/determination but also has largesweeping effects as an inflammatory cytokine of the TNF family; thus, it is a
therapeutic agent of interest in the low-grade inflammation present in obesity.
Moreover, obesity research often involves rat adipocyte models, for which there
are straightforward differentiation cocktails to utilize. These consist of 3 main
molecules, which bind to receptors that induce transcription of adipogenic genes.
Many papers have started to use another differentiation agent, Rosiglitazone, to
speed up the process; however, studies comparing differentiation levels with and
without are inconclusive or suggest no difference.
Thus, we aim to observe the effects of TWEAK in a murine adipocyte models to
determine if it has any lipolytic and anti-differentiation effects that would cause
anti-obesity effects.

Methodology
Cell culture: 3T3-L1 pre-adipocyte cells were sourced from
ATCC (ID: CL-173). Cells culture medium comprised of 10%
Bovine Calf Serum and 90% DMEM with 4.5 g/L glucose as per
ATCC recommendation. The cells were cultured in 100 mm
culture plates in a cell culture incubator set to 37 degrees
Celsius and 5% CO2. Cells were frozen immediately upon
arrival for 1 week, then thawed and subcultured near
confluency.
Oil Red O Staining: Oil Red O staining was done using a
StatLab kit (ID: KTORO) . Stained cells were cultured in LabTek II Chamber Slides. After medium was aspirated, plates
were washed with PBS, fixed with 10% formalin, then stained
with Oil Red O solution and modified Mayer’s Hematoxylin
solution. Slides are then removed from chamber and observed;
photos of slides were taken on an Olympus microscope with
digital camera.
RT-qPCR (primer selection): Target genes were decided
through literature analysis intended to find markers of
adipocyte differentiation, fatty acid synthesis, β-oxidation, and
lipolysis that are widely expressed 3T3-L1 cells or white
adipocyte tissues. Primers were found on PrimerBank, and
NCBI PrimerBlast was used to determine specificity. β-actin
was the housekeeping/reference gene used.
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Differentiation: Two differentiation protocols were utilized to assess
efficacy of thiazolidinediones in adipocyte differentiation.
Thiazolidinediones like are not present in ATCC protocols but are
becoming more popular in adipocyte differentiation. Differentiation
medium 1 is 90% DMEM, 10% FBS, 1.0 μM Dexamethasone, 0.5 mΜ
ΙΒΜΧ, and 1.0 μg/mL bovine insulin. Differentiation medium 2 follows
Sigma-Aldrich protocols: 90% DMEM/F12 (1:1), 10% FBS, 1.0 μM
Dexamethasone, 0.5 μΜ ΙΒΜΧ, 1.0 μg/mL bovine insulin, and an
added 1 μM Rosiglitazone, a thiazolidinedione PPARγ activator. After a
differentiation period of 48 hours adipocyte growth medium is used.
Growth medium 1 is 10% FBS, 90% DMEM, and 1 μg/mL insulin, and
growth medium 2 is 1 is 10% FBS, 90% DMEM/F12, and 1 μg/mL
insulin. TWEAK was added to the cells on the 10th day of
differentiation, and analysis was done on the 13th day. 4 6-well plates
and 4 Lab-Tek II Chamber Slides were differentiated using Protocol 2.
2 6-well plates, along with 4 Lab-Tek II Chamber Slides, were
differentiated using Protocol 1.

Figure 2: Protocol 2 Adipocytes without TWEAK treatment:
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ELISA standard protein results were graphed along with linear
regression of the standard curve. The absorbances of the NASH and
Chow-fed mice were then plotted on the regression line; since they were
diluted 10-fold, the real concentrations are 161.538 pg/mL in NASH mice
and 225.641 pg/ml in chow-fed mice. The two groups significantly differ,
with higher concentrations seemingly present in chow-fed mice.

Through oil red staining, triacylglycerol deposits in the cell become
clearly visible and highlighted amongst other parts of the cell. We can
use this to determine if cells have differentiated and to what degree.
Untreated Protocol 2 is clearly seen to have the highest % differentiation
and largest triacylglycerol level per cell. Untreated Protocol 1 is seen to
have remarkably less and splotchy differentiation. Protocol 2 TWEAK
treated cells have slightly rounder morphologies than their predifferentiated fibroblast form, suggesting that differentiation had partially
occurred, but TWEAK-treated adipocytes’ fat storages were markedly
small compared to untreated Protocol 2 and Protocol 1 adipocytes.

TWEAK is shown to inhibit differentiation and promote β-oxidation in 3T3-L1 pre-adipocyte cells; when
comparing Protocol 2 cells treated with TWEAK to those not treated with TWEAK, the reduced red staining
and more fusiform/spindle-like morphology of TWEAK-treated cells suggest that increased TWEAK
promotes higher β-oxidation of existing fat stores as well as inhibiting further differentiation of preadipocytes. This supports our hypothesis that increased TWEAK levels would hamper differentiation.

Moreover, circulating TWEAK levels were shown to be decreased in the blood of obese mice as compared
to normal mice. This supports our hypothesis and matches literature, which shows decreased immune
activity (including levels of CD8+ and NK cells, which are cells known to secrete soluble TWEAK). This
makes sense, as immunodeficiency and subsequent loss of TWEAK would increase adipocyte fatty acid
synthesis and pre-adipocyte differentiation.

Figure 4: Cocktail 2 Adipocytes with TWEAK treatment

Future Directions

Figure 5: RT-qPCR primers designed for TWEAK treated cells:
Gene Target Name
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Inversely, Protocol 2 adipocytes had higher percent differentiation and fatty acid synthesis than Protocol 1
adipocytes, as can be seen by the more rotund and more consistent morphology as well as larger lipid
stores/red dyed areas in Protocol 2 cells when compared to those differentiated through Protocol 1. This
demonstrates the effectiveness of thiazolidinedione agents like Rosiglitazone. This disproves our hypothesis
and some current literature, but it can be rationalized due to Dexamethasone’s similar mechanism of action.

Hypotheses
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Conclusion

Figure 1. (Hu, et al., 2017, pg. 3)
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TWEAK ELISA assay: Done using Invitrogen Mouse TWEAK ELISA kit
(ID: EMTNFSF12). Samples were collected from mice aged 2 months.
Blood serum samples were obtained from 3 control mice on a chowdiet and 3 obese mice on NASH diet. 50 μm serum was collected per
mouse, and serum was diluted 10-fold with diluent provided by the kit.
100 μL of dilute sample and dilute TWEAK standard protein was added
to appropriate wells and left to incubate overnight; following was the
addition of a biotin conjugate, then Streptavidin-HRP, and TMB
substrate with incubation and washing between each step. At the end,
stop solution was added without washing of the plate, and the plate’s
absorbance was read at 450 nm.

Figure 2: Protocol 1 Adipocytes (-Rosiglitazone):
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Figure 1: Pretreated/Prestained 3T3-L1 fibroblasts:
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Introduction

ADIPOR 1
ADIPOR 2
SREBP-1C
FAS
HSL

Forward Primer

Reverse Primer

GTGACGTTGACATCCGTAAAGA

GCCGGACTCATCGTACTCC

GGAAGACCACTCGCATTCCTT

GTAATCAGCAACCATTGGGTCA

AACATCGAGTGTCGAATATGTGG

CCGAATAGTTCGCCGAAAGAA

CTCCCGATTCATAATTGGGTCTG

TCGACCTTGTTTTACTAGGTGC

GAGACCCCTGTGTCGGTTC

CTGCGTGTGTGAAATGTCATTG

AATGGGGCTCCTTCTGGTAAC

GGATGACTCTCCAACGTCCCT

GCCAAACACCGATTGGGGT

GGCTCCAAATCTCCTTGGTAGTT

TGACCCGGCTATTCCGTGA

CTGGGCTGAGCAATACAGTTC

GGAGGTGGTGATAGCCGGTAT

TGGGTAATCCATAGAGCCCAG

GATTTACGCACGATGACACAGT

ACCTGCAAAGACATTAGACAGC

Although the various effects of TWEAK in adipocytes have been laid out in this
study, it is imperative that the mechanism and downstream cell signaling
pathways are further researched. Indeed, if a more targetable downstream
receptor or molecule exists that causes similar effects or an important
downstream signaling pathway that cannot be disturbed for fear of adverse effect,
it will greatly influence research on TWEAK. In that vein, the differentiated
Protocol 2 cells (control and TWEAK-treated) will be sent for RNA-seq in efforts to
try and elucidate possible downstream signaling pathways.
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